However, in barrier-protected tissues where tumor cells experience less antigenic stimulation, NF-κB pathway activation is particularly dependent on chronic B-cell receptor signaling and Toll-like receptor signaling maintained by CARD11, CD79B, and MYD88 mutations (31). This evidence concerns the gene CD79B and neoplasm.